Manuela Gariboldi

List of Publications by Year
in descending order

97 papers	9,167 citations	101543 36 h-index	46799 89 g-index
101 all docs	101 docs citations	101 times ranked	13771 citing authors

#	Article	IF	Citations
1	Force Sensing on Cells and Tissues by Atomic Force Microscopy. Sensors, 2022, 22, 2197.	3.8	12
2	Exploring the association with disease recurrence of miRNAs predictive of colorectal cancer. International Journal of Biological Markers, 2022, 37, 102-109.	1.8	0
3	Preventive Anti-inflammatory Diet to Reduce Gastrointestinal Inflammation in Familial Adenomatous Polyposis Patients: A Prospective Pilot Study. Cancer Prevention Research, 2021, 14, 963-972.	1.5	8
4	Management of Dietary Habits and Diarrhea in Fap Individuals: A Mediterranean Low-Inflammatory Dietary Intervention. Nutrients, 2021, 13, 3988.	4.1	2
5	Plasma miRNAâ€based signatures in CRC screening programs. International Journal of Cancer, 2020, 146, 1164-1173.	5.1	35
6	Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy. OncoImmunology, 2020, 9, 1774298.	4.6	22
7	A Pilot Low-Inflammatory Dietary Intervention to Reduce Inflammation and Improve Quality of Life in Patients With Familial Adenomatous Polyposis: Protocol Description and Preliminary Results. Integrative Cancer Therapies, 2019, 18, 153473541984640.	2.0	10
8	Workflow for Circulating miRNA Identification and Development in Cancer Research: Methodological Considerations. , 2018, , 103-117.		1
9	A methodological procedure for evaluating the impact of hemolysis on circulating microRNAs. Oncology Letters, 2017, 13, 315-320.	1.8	52
10	MIF/CD74 axis is a target for novel therapies in colon carcinomatosis. Journal of Experimental and Clinical Cancer Research, 2017, 36, 16.	8.6	43
11	Metformin transiently inhibits colorectal cancer cell proliferation as a result of either AMPK activation or increased ROS production. Scientific Reports, 2017, 7, 15992.	3.3	102
12	Abstract B19: Disruption of energy homeostasis as an approach to block the proliferation of colon carcinomatosis. , 2017, , .		0
13	Comment on â€˜Circulating cell-free miRNAs as biomarker for triple-negative breast cancerâ€™â€”Methodological challenges in combining miRNAs as circulating biomarkers. British Journal of Cancer, 2016, 114, e5-e5.	6.4	2
14	miR-342 overexpression results in a synthetic lethal phenotype in BRCA1-mutant HCC1937 breast cancer cells. Oncotarget, 2016, 7, 18594-18604.	1.8	20
15	Integration of genome scale data for identifying new players in colorectal cancer. World Journal of Gastroenterology, 2016, 22, 534.	3.3	3
16	Moving from Discovery to Validation in Circulating microRNA Research. International Journal of Biological Markers, 2015, 30, 258-261.	1.8	2
17	The Effects of miRâ€20a on p21: Two Mechanisms Blocking Growth Arrest in TGFâ€Î²â€Responsive Colon Carcinoma. Journal of Cellular Physiology, 2015, 230, 3105-3114.	4.1	46
18	DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. British Journal of Clinical Pharmacology, 2015, 80, 581-588.	2.4	52

#	Article	IF	Citations
19	Abstract 1161: Metformin has an inhibitory effect on cell proliferation but does not induce death in colorectal cancer. , 2015, , .		3
20	Abstract CT121: Metronomic capecitabine and bevacizumab is an active combination in patients with relapsed peritoneal pseudomyxoma. , 2015, , .		0
21	A normalization strategy for the analysis of plasma microRNA qPCR data in colorectal cancer. International Journal of Cancer, 2014, 134, 2016-2018.	5.1	8
22	Combined analysis of chromosomal instabilities and gene expression for colon cancer progression inference. Journal of Clinical Bioinformatics, 2014, 4, 2.	1.2	15
23	Circulating miR-378 in plasma: a reliable, haemolysis-independent biomarker for colorectal cancer. British Journal of Cancer, 2014, 110, 1001-1007.	6.4	118
24	Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. Annals of Oncology, 2014, 25, 404-408.	1.2	67
25	NqA: An R-based algorithm for the normalization and analysis of microRNA quantitative real-time polymerase chain reaction data. Analytical Biochemistry, 2014, 461, 7-9.	2.4	15
26	Circulating Free DNA in a Screening Program for Early Colorectal Cancer Detection. Tumori, 2014, 100, 115-121.	1.1	39
27	miR-342 Regulates BRCA1 Expression through Modulation of ID4 in Breast Cancer. PLoS ONE, 2014, 9, e87039.	2.5	59
28	Circulating free DNA in a screening program for early colorectal cancer detection. Tumori, 2014, 100, 115-21.	1.1	27
29	Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects. Oncogene, 2013, 32, 1475-1487.	5.9	204
30	Gold-Nanoparticle-Based Colorimetric Discrimination of Cancer-Related Point Mutations with Picomolar Sensitivity. ACS Nano, 2013, 7, 5530-5538.	14.6	101
31	Role of cMET in the Development and Progression of Colorectal Cancer. International Journal of Molecular Sciences, 2013, 14, 18056-18077.	4.1	47
32	Effects of Warm Ischemic Time on Gene Expression Profiling in Colorectal Cancer Tissues and Normal Mucosa. PLoS ONE, 2013, 8, e53406.	2.5	44
33	Copyâ€“Number Alterations for Tumor Progression Inference. Lecture Notes in Computer Science, 2013, , 104-109.	1.3	11
34	miRNA Profiling in Colorectal Cancer Highlights miR-1 Involvement in MET-Dependent Proliferation. Molecular Cancer Research, 2012, 10, 504-515.	3.4	123
35	Methylation status in patients with early stage colon cancer: A new prognostic marker?. International Journal of Cancer, 2012, 130, 488-489.	5.1	10
36	Abstract 2295: miR-342 modulates ID4 expression in breast cancer. , 2012, , .		0

#	Article	IF	Citations
37	Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer. Breast Cancer Research and Treatment, 2011, 127, 601-610.	2.5	88
38	Transcriptional characteristics of familial nonâ€BRCA1/BRCA2 breast tumors. International Journal of Cancer, 2011, 128, 2635-2644.	5.1	11
39	ERG Deregulation Induces PIM1 Over-Expression and Aneuploidy in Prostate Epithelial Cells. PLoS ONE, 2011, 6, e28162.	2.5	25
40	Abstract 3959: Growth suppression by TGF-Î² in responsive colon carcinoma is opposed by miR-20a through mechanisms altering p21WAF1 up-regulation. , 2011, , .		0
41	Chromosome band 17q21 in breast cancer: Significant association between beclin 1 loss and HER2/NEU amplification. Genes Chromosomes and Cancer, 2010, 49, 901-909.	2.8	41
42	Molecular markers for prediction of risk of radiation-related injury to normal tissue. Journal of Nucleic Acids Investigation, 2010, 1, 11.	0.8	2
43	Abstract 4038: Identification of microRNAs involved in colorectal cancer progression. , 2010, , .		0
44	Molecular markers for prediction of risk of radiation-related injury to normal tissue. Journal of Nucleic Acids Investigation, 2010, 1, 11.	0.8	4
45	Misbehaviour of XIST RNA in Breast Cancer Cells. PLoS ONE, 2009, 4, e5559.	2.5	75
46	Integrative approach for prioritizing cancer genes in sporadic colon cancer. Genes Chromosomes and Cancer, 2009, 48, 953-962.	2.8	47
47	Gene expression profiling integrated into network modelling reveals heterogeneity in the mechanisms of BRCA1 tumorigenesis. British Journal of Cancer, 2009, 101, 1469-1480.	6.4	13
48	To Bleed or Not to Bleed. A Prediction Based on Individual Gene Profiling Combined With Doseâ€"Volume Histogram Shapes in Prostate Cancer Patients Undergoing Three-Dimensional Conformal Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1431-1440.	0.8	55
49	Invasiveness gene signature predicts a favorable outcome also in estrogen receptor-positive primary breast cancers treated with adjuvant tamoxifen. Breast Cancer Research and Treatment, 2008, 111, 389-390.	2.5	3
50	Metallothionein 1G acts as an oncosupressor in papillary thyroid carcinoma. Laboratory Investigation, 2008, 88, 474-481.	3.7	60
51	Re: Molecular Basis for Estrogen Receptor Â Deficiency in BRCA1-Linked Breast Cancer. Journal of the National Cancer Institute, 2008, 100, 752-753.	6.3	2
52	Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer. Endocrine-Related Cancer, 2008, 15, 439-449.	3.1	16
53	Challenges in Projecting Clustering Results Across Gene Expressionâ€"Profiling Datasets. Journal of the National Cancer Institute, 2007, 99, 1715-1723.	6.3	88
54	Analysis of gene expression identifies PLAB as a mediator of the apoptotic activity of fenretinide in human ovarian cancer cells. Oncogene, 2007, 26, 3952-3962.	5.9	14

#	Article	IF	Citations
55	Transcriptional network dynamics in macrophage activation. Genomics, 2006, 88, 133-142.	2.9	125
56	Specific gene expression profiles distinguish among functional allelic variants of the mouse Pthlh gene in transfected human cancer cells. Oncogene, 2006, 25, 4501-4504.	5.9	8
57	Molecular predictors of response and outcome in ovarian cancer. Critical Reviews in Oncology/Hematology, 2006, 60, 19-37.	4.4	36
58	Regulation of lipocalin-2 gene by the cancer chemopreventive retinoid 4-HPR. International Journal of Cancer, 2006, 119, 1599-1606.	5.1	15
59	Mâ€CAM expression as marker of poor prognosis in epithelial ovarian cancer. International Journal of Cancer, 2006, 119, 1920-1926.	5.1	78
60	Gene expression profile identifies a rare epithelioid variant case of pleomorphic liposarcoma carrying FUS-CHOP transcript. Histopathology, 2005, 46, 334-341.	2.9	21
61	RESPONSE: Re: Limits of Predictive Models Using Microarray Data for Breast Cancer Clinical Treatment Outcome. Journal of the National Cancer Institute, 2005, 97, 1852-1853.	6.3	2
62	Re: Limits of Predictive Models Using Microarray Data for Breast Cancer Clinical Treatment Outcome. Journal of the National Cancer Institute, 2005, 97, 1851-1852.	6.3	10
63	Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 14825-14830.	7.1	311
64	Limits of Predictive Models Using Microarray Data for Breast Cancer Clinical Treatment Outcome. Journal of the National Cancer Institute, 2005, 97, 927-930.	6.3	110
65	The Transcriptional Landscape of the Mammalian Genome. Science, 2005, 309, 1559-1563.	12.6	3,227
66	Gene discovery in genetically labeled single dopaminergic neurons of the retina. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 5069-5074.	7.1	70
67	CTAB-Urea Method Purifies RNA from Melanin for cDNA Microarray Analysis. Pigment Cell & Melanoma Research, 2004, 17, 312-315.	3.6	26
68	Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2. Oncogene, 2004, 23, 8171-8183.	5.9	75
69	Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene, 2004, 23, 7436-7440.	5.9	239
70	VE-Cadherin Expression and Clustering Maintain Low Levels of Survivin in Endothelial Cells. American Journal of Pathology, 2004, 165, 181-189.	3.8	34
71	Allele-specific patterns of the mouse parathyroid hormone-related protein: influences on cell adhesion and migration. Oncogene, 2003, 22, 7711-7715.	5.9	8
72	Gene expression profile of normal lungs predicts genetic predisposition to lung cancer in mice. Carcinogenesis, 2003, 24, 1819-1826.	2.8	10

#	Article	IF	Citations
73	Stearoyl-CoA desaturase 1 (Scd1) gene overexpression is associated with genetic predisposition to hepatocarcinogenesis in mice and rats. Carcinogenesis, 2002, 23, 1933-1936.	2.8	81
74	Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature, 2002, 420, 563-573.	27.8	1,548
75	Functional annotation of a full-length mouse cDNA collection. Nature, 2001, 409, 685-690.	27.8	653
76	A cancer modifier role for parathyroid hormone-related protein. Oncogene, 2000, 19, 5324-5328.	5.9	28
77	Genetic mapping and analysis of mouse p27 Kip1 gene as Pas1 candidate gene. Mammalian Genome, 2000, 11, 338-339.	2.2	0
78	Predisposition to lung tumorigenesis. Toxicology Letters, 2000, 112-113, 257-263.	0.8	13
79	Analysis of loss of heterozygosity in neoplastic nodules induced by diethylnitrosamine in the resistant BFF1 rat strain. Carcinogenesis, 1999, 20, 1363-1368.	2.8	9
80	Linkage Disequilibrium and Physical Mapping of Pas1 in Mice. Genome Research, 1999, 9, 639-646.	5.5	35
81	Analysis of the retinoic acid receptor Î± gene as a candidate for the pulmonary adenoma resistance 1 gene. Molecular Carcinogenesis, 1998, 21, 13-16.	2.7	2
82	Pas1 is a common lung cancer susceptibility locus in three mouse strains. Mammalian Genome, 1997, 8, 801-804.	2.2	25
83	Genetic mapping of a pulmonary adenoma resistance locus (Par1) in mouse. Nature Genetics, 1996, 12, 455-457.	21.4	64
84	Analysis of loss of heterozygosity in murine hepatocellular tumors. Molecular Carcinogenesis, 1995, 13, 191-200.	2.7	23
85	Genetic mapping and expression analysis of the murine DNA ligase I gene. Molecular Carcinogenesis, 1995, 14, 71-74.	2.7	9
86	Mapping of the Hmg1 gene and of seven related sequences in the mouse. Mammalian Genome, 1995, 6, 581-585.	2.2	21
87	Chromosome mapping of nine tropomyosin-related sequences in mice. Mammalian Genome, 1995, 6, 273-277.	2.2	2
88	Mapping of body weight loci on mouse Chromosome X. Mammalian Genome, 1995, 6, 778-781.	2.2	70
89	Different Susceptibility to Lung Tumorigenesis in Mice with an IdenticalKras2Intron 2. Genomics, 1995, 29, 438-444.	2.9	33
90	Genetics of liver tumor susceptibility in mice. Toxicology Letters, 1995, 82-83, 613-619.	0.8	28

#	Article	IF	Citations
91	Expression in lung tumors and genetic mapping of the novel murine protein kinase Cî·. Molecular Carcinogenesis, 1994, 9, 111-113.	2.7	4
92	Comparative Mapping of the Actin-Binding Protein 280 Genes in Human and Mouse. Genomics, 1994, 21, 428-430.	2.9	21
93	Genetic Mapping of the Mouse CDC25Mm Gene, a Ras-Specific Guanine Nucleotide-Releasing Factor, to Chromosome 9. Genomics, 1994, 21, 451-453.	2.9	12
94	Multiple Loci Affect Genetic Predisposition to Hepatocarcinogenesis in Mice. Genomics, 1994, 23, 118-124.	2.9	93
95	A major susceptibility locus to murine lung carcinogenesis maps on chromosome 6. Nature Genetics, 1993, 3, 132-136.	21.4	127
96	Esophageal Carcinoma. Acta Radiologica, 1987, 28, 177-180.	1.1	2
97	Esophageal Carcinoma. Acta Radiologica, 1987, 28, 177-180.	1.1	1